Some of the most lethal cancers in existence — small cell lung cancer, small cell prostate cancer, and related neuroendocrine tumors — have something in common: they almost universally lose a protective gene called RB, and they have resisted new therapeutic approaches for decades. A study from UCLA Health has now identified a hidden vulnerability in these tumors that may open a new treatment path, and existing FDA-approved drugs may already be positioned to exploit it.
The research, published March 20, 2026, in Proceedings of the National Academy of Sciences, found that when RB is lost, these cancer cells become critically dependent on a protein called E2F3 for survival. Block E2F3, and the cancer cells cannot survive — a mechanism scientists call "synthetic lethality."
The most immediate implication: an existing class of FDA-approved drugs called DHODH inhibitors — used in clinical practice for autoimmune diseases like rheumatoid arthritis — can lower E2F3 levels and slow tumor growth in laboratory models.
Why This Matters
Small cell lung cancer is among the most lethal cancers a person can receive. Median survival even with current standard treatment is approximately 12 months, according to UCLA Health. The five-year survival rate for all stages combined is approximately 7%. Treatment options have been largely the same for over two decades — chemotherapy with or without immunotherapy.
Small cell neuroendocrine cancers of the prostate represent a similarly difficult-to-treat group, often arising when prostate cancer evolves to resist hormone therapy. The lung, prostate, and ovarian versions of small cell neuroendocrine cancer share the same RB-loss biology — which is why the UCLA finding potentially applies across multiple cancer types, not just lung cancer.
What We Know So Far
From UCLA Health's press release, ScienceDaily, and the published PNAS study:
- The finding : When the RB gene is absent (as it is in virtually all small cell cancers), cancer cells become heavily dependent on the transcription factor E2F3 to survive — a state of "synthetic lethality" where the cancer cell cannot survive the simultaneous loss of both RB and E2F3
- Laboratory result : Blocking E2F3 in cell line and animal models of small cell cancer consistently halted tumor growth
- The drug connection : Because no approved drugs currently target E2F3 directly, researchers explored blocking the DHODH enzyme — which regulates the metabolic pathway that controls E2F3 levels. Inhibiting DHODH lowered E2F3 levels and slowed tumor growth
- Existing FDA-approved drugs : DHODH inhibitors leflunomide and teriflunomide are already FDA-approved for rheumatoid arthritis and multiple sclerosis, respectively — potentially accelerating the timeline to clinical evaluation in cancer
"Discovering a vulnerability like this opens the door to thinking about entirely new treatment strategies," said study senior author Dr. Owen N. Witte, a distinguished professor and director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA.
"What's exciting is that our findings open the door to applying existing drugs in a new way," said study co-author Evan Abt.
Where the Research Stands
This research is pre-clinical. The results are from cancer cell lines and animal models, not human clinical trials. The gap between a laboratory finding and an approved clinical treatment is real and substantial — even for studies involving drugs that are already FDA-approved for other indications, re-purposing requires its own clinical trial evidence for safety and efficacy in the new indication.
The path forward for DHODH inhibitors in RB-deficient small cell cancers requires: additional pre-clinical validation, toxicology assessment in cancer patient populations (who differ from autoimmune patients), Phase I safety trials, and Phase II efficacy trials. That process typically spans three to seven years, even under accelerated circumstances.
What the Evidence Shows — and What It Does Not
MedicalDaily Evidence Check
- Study type : Pre-clinical — cell line and animal model experiments
- Published in : Proceedings of the National Academy of Sciences (March 20, 2026)
- Institution : UCLA Health (Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research)
- Key finding : E2F3 is a synthetic lethal vulnerability in RB-deficient small cell cancers; DHODH inhibition lowers E2F3 and slows tumor growth in laboratory models
- Existing drug connection : Leflunomide and teriflunomide (FDA-approved for rheumatoid arthritis and MS) are DHODH inhibitors that could potentially be tested in cancer
- What it did not prove : Clinical efficacy or safety in human cancer patients; no clinical trials have been completed or announced
- What it accelerates : The pre-existing FDA approval of DHODH inhibitors removes some early-stage development hurdles — but cancer clinical trials would still be required
- What readers should know : This is a meaningful pre-clinical finding with a realistic path to clinical investigation; no approved treatment change has occurred
Who May Eventually Benefit?
If clinical trials confirm the findings:
- Patients with small cell lung cancer — approximately 30,000 Americans diagnosed annually
- Patients with small cell neuroendocrine prostate cancer, particularly those who have developed resistance to hormone therapy
- Patients with small cell neuroendocrine cancers of the ovary
- All of these patient populations are currently underserved by available targeted therapies
Symptoms and Warning Signs to Watch For
Small cell lung cancer symptoms that should prompt evaluation:
- Persistent cough, including coughing up blood
- Shortness of breath or wheezing that does not resolve
- Chest pain
- Unexplained weight loss and fatigue
- Hoarse voice or difficulty swallowing
Small cell neuroendocrine cancers can also produce hormonal symptoms depending on the tissues involved. Any of these symptoms in a current or former smoker warrants urgent clinical evaluation.
What You Can Do Now
- If you or a family member has small cell lung cancer or small cell neuroendocrine cancer , ask your oncologist specifically whether DHODH inhibitors are being investigated in any active clinical trials for which you might be eligible.
- Search ClinicalTrials.gov for active trials in RB-deficient small cell cancers or DHODH inhibition in neuroendocrine tumors.
- Do not seek leflunomide or teriflunomide as cancer treatments outside of a clinical trial. These drugs have significant side effects in autoimmune patients and have not been tested for safety or efficacy in cancer patients.
- Contact Lung Cancer Research Foundation or CancerCare for information on current trial availability and patient navigator support.
Cost and Access: What Patients Should Know
Participation in clinical trials is typically at no cost for the experimental treatment itself, though other expenses may vary. The National Cancer Institute's Cancer Information Service helps patients find and evaluate trial options, including eligibility assistance.
What Happens Next
The UCLA team is expected to advance to more comprehensive pre-clinical testing of DHODH inhibitors in small cell cancer models, followed by potential IND application to the FDA for a Phase I human trial. The existing FDA approval of leflunomide and teriflunomide removes one regulatory hurdle, but a formal new indication requires full clinical evidence.
The Bottom Line
UCLA researchers have identified a genuine molecular vulnerability in small cell neuroendocrine cancers — tumors that have barely changed in treatability for three decades. The synthetic lethality between RB loss and E2F3 dependence creates a target. The fact that existing, already-approved drugs inhibit the pathway that controls E2F3 expression means the laboratory-to-clinical pathway is shorter than for entirely novel agents. This is early-stage research, but it represents exactly the kind of mechanistic discovery that eventually becomes the basis for a new treatment.
